Public health science campus
Public Health England (PHE) is developing a public health science campus and headquarters in Harlow, Essex, UK.
Named PHE Harlow, the facility is estimated to cost £400m ($584m), which will be funded by the UK Government through a capital support programme.
The campus is expected to deliver solutions for issues such as smoking, alcohol, diabetes, dementia and environmental hazards. PHE aims to support the training of scientists in the research centre to meet future recruitment needs.
Construction is expected to commence in 2019 and is scheduled for completion by 2024.
The project is expected to generate employment for up to 2,750 people by 2024. It is also expected to generate thousands of construction-related jobs.
The Harlow Council’s Development Management Committee granted approval to develop the health science campus in December 2017 on a site formerly owned by pharmaceutical company GlaxoSmithKline (GSK).
The site is located at the company’s New Frontiers Science Park within the Pinnacles Industrial Estate in Harlow and within the London-Stansted-Cambridge life sciences corridor (LSSC), which is one of the leading life sciences research zones in Europe.
The LSSC corridor comprises 37 life sciences research institutes and 1,400 life sciences businesses. It is expected to create an opportunity for PHE to partner with commercial, academic and government partners.
A business case for the establishment of the PHE Harlow project was submitted to the UK Government in July 2014.
PHE announced its decision to relocate the majority of its functions from Porton to Harlow in September 2015. The decision was followed by a government proposal announced in November 2015 to move the Colindale facilities to Harlow and create a single centralised campus.
In addition to the Porton and Colindale facilities, the Central London headquarters of PHE is also proposed to be relocated.
The design of the PHE Harlow campus includes the construction of a new reception and visitor centre, an exhibition space, a training laboratory and a media centre.
A specialist bioscience laboratory building and logistics centre will also be added, the existing laboratories and office areas will be refurbished and site-wide infrastructure will be installed.
Four of the existing buildings created by GSK will be refurbished and reused, retaining 64,000m² of floor space. The draft proposal includes construction of up to 56,000m² of new floor space, including 9,000m² for future expansion.
The visitor area of the campus will allow school groups and organisations in the local community to meet PHE scientists, attend conferences and workshops, and learn about public health, science and research.
Kier Group was awarded a contract worth £160m ($221m) for the construction of the specialist bioscience laboratory building.
Wates Construction was awarded a contract for the construction of the arrivals, administration, and logistics buildings, as well as for renovating the main building, including laboratories and offices.
VolkerFitzpatrick (Royal VolkerWessels) was contracted for the installation of infrastructure, external works, and construction of an energy centre within the campus.
Alnylam Pharmaceuticals is constructing a new drug substance manufacturing and cGMP warehouse facility in Norton, Massachusetts, US. The company broke…
Neopharma opened a pharmaceutical plant in Abu Dhabi, United Arab Emirates, in July 2003. The plant then entered a three-month…
French pharmaceutical company Sanofi’s manufacturing plant in Goa, India, is located in the Verna Industrial Park, owned by Sanofi’s Indian…
GlaxoSmithKline (GSK) began construction of an oral solid-dose manufacturing plant at the Vemgal Industrial Area in India in September 2015.…